Dexamethasone acetateCAS# 1177-87-3 |
- A-71623
Catalog No.:BCC7354
CAS No.:130408-77-4
- SR 27897
Catalog No.:BCC7277
CAS No.:136381-85-6
- CCK Octapeptide, non-sulfated
Catalog No.:BCC5709
CAS No.:25679-24-7
- Proglumide sodium salt
Catalog No.:BCC5768
CAS No.:99247-33-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1177-87-3 | SDF | Download SDF |
| PubChem ID | 236702 | Appearance | Powder |
| Formula | C24H31FO6 | M.Wt | 434.5 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Dexamethasone 21-acetate | ||
| Solubility | DMSO : 50 mg/mL (115.07 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
| Chemical Name | [2-[(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate | ||
| SMILES | CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)COC(=O)C)O)C)O)F)C | ||
| Standard InChIKey | AKUJBENLRBOFTD-RPRRAYFGSA-N | ||
| Standard InChI | InChI=1S/C24H31FO6/c1-13-9-18-17-6-5-15-10-16(27)7-8-21(15,3)23(17,25)19(28)11-22(18,4)24(13,30)20(29)12-31-14(2)26/h7-8,10,13,17-19,28,30H,5-6,9,11-12H2,1-4H3/t13-,17+,18+,19+,21+,22+,23+,24+/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Dexamethasone acetate is a glucocorticoid receptor agonist.In Vitro:Dexamethasone regulates several transcription factors, including activator protein-1, nuclear factor-AT, and nuclear factor-kB, leading to the activation and repression of key genes involved in the inflammatory response[1]. Dexamethasone potently inhibits granulocyte-macrophage colony stimulating factor (GM-CSF) release from A549 cells with EC50 of 2.2 nM. Dexamethasone (EC50=36 nM) induces transcription of the β2-receptor is found to correlate with glucocorticoid receptor (GR) DNA binding and occurred at 10-100 fold higher concentrations than the inhibition of GM-CSF release. Dexamethasone (IC50=0.5 nM) inhibits a 3×κB (NF-κB, IκBα, and I-κBβ), which is associated with inhibition of GM-CSF release[2].In Vivo:It has previously been reported that treatment with Dexamethasone at a dose of 2×5 mg/kg efficiently inhibits lipopolysaccharide (LPS)-induced inflammation. In our experimental system, treatment with a single dose of Dexamethasone 10 mg/kg (i.p.) significantly decreases recruitment of granulocytes as well as spontaneous production of oxygen radicals compared with animals expose to LPS and injected with solvent alone (saline). The effects are statistically significant when administered both 1 h before and 1 h after inhalation of LPS. The number of granulocytes in BALF decreased to levels comparable to healthy animals (given an aerosol of water)[3]. Rats treated with Dexamethasone consume less food and weighed less than control rats. Treated rats also weigh less than pair-fed animals though their food intake is similar. Five days of Dexamethasone injection result in a significant increase in both the liver mass (+42%) and the liver to body weight ratio (+65%). The wet weight of gastrocnemius muscle decreases 20% after 5 days of treatment, but it remains unaffected relative to body weight (g/100 g body weight), indicating that muscle weight loss paralleled body weight loss[4]. References: | |||||
Dexamethasone acetate Dilution Calculator
Dexamethasone acetate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.3015 mL | 11.5075 mL | 23.015 mL | 46.0299 mL | 57.5374 mL |
| 5 mM | 0.4603 mL | 2.3015 mL | 4.603 mL | 9.206 mL | 11.5075 mL |
| 10 mM | 0.2301 mL | 1.1507 mL | 2.3015 mL | 4.603 mL | 5.7537 mL |
| 50 mM | 0.046 mL | 0.2301 mL | 0.4603 mL | 0.9206 mL | 1.1507 mL |
| 100 mM | 0.023 mL | 0.1151 mL | 0.2301 mL | 0.4603 mL | 0.5754 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs that has anti-inflammatory and immunosuppressant properties.
- Laxogenin
Catalog No.:BCN8434
CAS No.:1177-71-5
- DL-Syringaresinol
Catalog No.:BCN6053
CAS No.:1177-14-6
- LY 255283
Catalog No.:BCC7290
CAS No.:117690-79-6
- Agomelatine hydrochloride
Catalog No.:BCC4210
CAS No.:1176316-99-6
- 3-Cyano-7-ethoxycoumarin
Catalog No.:BCC7979
CAS No.:117620-77-6
- 16-Oxocleroda-3,13E-dien-15-oic acid
Catalog No.:BCN7286
CAS No.:117620-72-1
- 1-Hydroxy-1-(4-hydroxy-2-methoxyphenyl)-3-(4-hydroxyphenyl)propan-2-one
Catalog No.:BCN1607
CAS No.:117614-84-3
- 6-Hydroxymethylherniarin
Catalog No.:BCN3573
CAS No.:117597-79-2
- Coronarin E
Catalog No.:BCN6052
CAS No.:117591-81-8
- Calpeptin
Catalog No.:BCC2351
CAS No.:117591-20-5
- DMXAA (Vadimezan)
Catalog No.:BCC3644
CAS No.:117570-53-3
- threo-6'-Hydroxyustusolate C
Catalog No.:BCN6930
CAS No.:1175543-07-3
- Doramectin
Catalog No.:BCC1536
CAS No.:117704-25-3
- CKI 7 dihydrochloride
Catalog No.:BCC5614
CAS No.:1177141-67-1
- (R)-(+)-Blebbistatin
Catalog No.:BCC7195
CAS No.:1177356-70-5
- Felbamate hydrate
Catalog No.:BCC4160
CAS No.:1177501-39-1
- Forsythoside I
Catalog No.:BCN6430
CAS No.:1177581-50-8
- N20C hydrochloride
Catalog No.:BCC7292
CAS No.:1177583-87-7
- SMANT hydrochloride
Catalog No.:BCC6254
CAS No.:1177600-74-6
- CGH 2466 dihydrochloride
Catalog No.:BCC7338
CAS No.:1177618-54-0
- Azithromycin Dihydrate
Catalog No.:BCC4631
CAS No.:117772-70-0
- Decumbenine C
Catalog No.:BCC8314
CAS No.:117772-89-1
- Desmethyl-YM 298198
Catalog No.:BCC7365
CAS No.:1177767-57-5
- AP-III-a4
Catalog No.:BCC5292
CAS No.:1177827-73-4
Mucoadhesive dexamethasone acetate-polymyxin B sulfate cationic ocular nanoemulsion--novel combinatorial formulation concept.[Pubmed:27455551]
Pharmazie. 2016 Jun;71(6):327-33.
Dexamethasone acetate (DEX) and polymyxin B sulfate (polymyxin B) were formulated as a cationic nanoemulsion for the treatment of ophthalmic infections. As novel concept, the positive charge to achieve mucoadhesion was not generated by toxicologically and regulatorily problematic cationic lipids or polymers, but by using a positively charged drug in combination with positively charged preservatives. The preservative also acts as co-surfactant to stabilize the emulsion. Nanoemulsions with the lipid phase Eutanol G-Lipoid S 100 (70%:30%) containing 0.05% (w/w) DEX were produced by high pressure homogenization, followed by dissolving the hydrophilic molecules in the water phase, e.g. polymyxin B (0.1%, w/w), cetylpyridinium chloride (0.01%, w/w) and glycerol (2.6%, w/w) to yield a combination product. The particles were below 200 nm with narrow size distribution. The osmolality (374 mOsm/kg), pH (5.31) and viscosity (2.45 mPa s at 37 degrees C) were compatible to the ocular administration. The zeta potential of the optimized formulation was shifted from approx. +9 mV to -11 mV after mucin incubation. The in vitro test revealed no potential cytotoxicity. The final products were stable after 180 days of storage at 4 degrees C and room temperature. The developed product is a viable alternative to the commercial ophthalmic suspensions. Moreover, this concept of generating the positive charge by cationic drug and/or preservative addition can be transferred to other ophthalmic products.
Dexamethasone and acetate modulate cytoplasmic leptin in bovine preadipocytes.[Pubmed:25049989]
Asian-Australas J Anim Sci. 2014 Apr;27(4):567-73.
Hormonal and nutrient signals regulate leptin synthesis and secretion. In rodents, leptin is stored in cytosolic pools of adipocytes. However, not much information is available regarding the regulation of intracellular leptin in ruminants. Recently, we demonstrated that leptin mRNA was expressed in bovine intramuscular preadipocyte cells (BIP cells) and that a cytoplasmic leptin pool may be present in preadipocytes. In the present study, we investigated the expression of cytoplasmic leptin protein in BIP cells during differentiation as well as the effects of various factors added to the differentiation medium on its expression in BIP cells. Leptin mRNA expression was observed only at 6 and 8 days after adipogenic induction, whereas the cytoplasmic leptin concentration was the highest on day 0 and decreased gradually thereafter. Cytoplasmic leptin was detected at 6 and 8 days after adipogenic induction, but not at 4 days after adipogenic induction. The cytoplasmic leptin concentration was reduced in BIP cells at 4 days after treatment with dexamethasone, whereas cytoplasmic leptin was not observed at 8 days after treatment. In contrast, acetate significantly enhanced the cytoplasmic leptin concentration in BIP cells at 8 days after treatment, although acetate alone did not induce adipocyte differentiation in BIP cells. These results suggest that dexamethasone and acetate modulate the cytoplasmic leptin concentration in bovine preadipocytes.
Topical delivery of dexamethasone acetate from hydrogel containing nanostructured liquid carriers and the drug.[Pubmed:25940221]
Arch Pharm Res. 2015 Nov;38(11):1999-2007.
The potential of hydrogel containing nanostructured lipid carriers (NLC) to enhance the skin permeation rate and skin deposition of Dexamethasone acetate (DEA) was investigated. The particle size of obtained NLCs was around 224.4 nm. NLCs had core-shell structure and DEA existed in amorphous state in NLCs. The permeation rate of DEA through excised mouse skins from hydrogel containing DEA-NLC (DEA-NLC-hydrogel) was 7.3 times higher than DEA-ointment. The skin deposition of DEA from DEA-NLC-hydrogel increased 3.8 folds compared to that from solution of DEA in hydrogel (DEA-hydrogel).
Changes of Spleen in Wistar Rats Exposed to Therapeutic Doses of Dexamethasone and Medroxyprogesterone Acetate Evaluated by Stereological Parameters.[Pubmed:27442392]
Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2015;36(3):13-25.
The aim of our investigation was to evaluate the immunosuppressive effect of medroxyprogesterone acetate (MPA) determining the volume densities of the structural components of the spleen. The volume densities of the same structural components of spleen were determined after administration of dexamethasone too, in order to see whether the morphological changes induced by MPA are in the same line with the changes caused by dexamethasone. 60 female Wistar rats were divided into 5 groups. The control group of rats was administered physiological solution. The remaining, 4 experimental groups were administered: dexamethasone at a therapeutic daily dose of 0.6 mg/kg bw and maximal therapeutic dose of 3 mg/kg bw, and MPA at a therapeutic dose of 30 mg/kg bw and maximal therapeutic dose of 150 mg/kg bw. The drugs were applied intramuscularly for 7 days. Spleen paraffin sections were stained according to the methods: hematoxylin-eosin, Masson and Elastica van-Gieson. Stereological measurements were performed by using the Weibl's multipurpose test system (M-42). The histological analyses of the structural components of the spleen in rats treated with dexamethasone and MPA have shown reduction of the white pulp and the marginal zone and an apparent decrease of the cellular density of the lymphocyte component of the pulp. The stereological analysis of the spleen showed significant decrease of the splenic pulp volume density and significant increase of the connective tissue volume density. Reducing the presence of splenic pulp was mainly due to the decrease in the volume density of all structural components of the white pulp. Changes were observed in all drug treated groups of rats. Our results have shown that the MPA provoked changes suggested atrophy of the spleen lymphoid tissue. Although the atrophic changes of the spleen were significant after the application of both dexamethasone and MPA, the white pulp was significantly more sensitive substrate for dexamethasone than for the MPA.
